The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | A Phase Ib study of add-on therapy with CK0804 in myelofibrosis with suboptimal ruxolitinib response
Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the promising results of a Phase Ib study investigating add-on therapy with cord blood-derived, CXCR4-enriched T regulatory cells (CK0804) in patients with myelofibrosis (MF) and suboptimal response to ruxolitinib treatment. The safety run-in has shown positive safety results, and the preliminary efficacy in symptom reduction has been encouraging. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
